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ABSTRACT
Objectives: Many different factors affect the transferability of cost-
effectiveness results between countries. The objective is to quantify the
impact of nine potential causes of variation in cost-effectiveness of phar-
macological smoking cessation therapies (SCTs) between The Netherlands
(reference case), Germany, Sweden, UK, Belgium, and France.
Methods: The life-time beneﬁts of smoking cessation were calculated
using the Beneﬁts of Smoking Cessation on Outcomes model, following a
cohort of smokers making an unaided quit attempt, or using nicotine
replacement therapy (NRT), bupropion, or varenicline. We investigated
the impact of between-country differences in nine factors—demography,
smoking prevalence, mortality, epidemiology and costs of smoking-
related diseases, resource use and unit costs of SCTs, utility weights and
discount rates—on the incremental net monetary beneﬁt (INMB), using
a willingness-to-pay (WTP) of €20,000 per quality adjusted life year
(QALY).
Results: The INMB of 1000 quit attempts with NRT versus unaided,
varies from €0.39 million (Germany) to €1.47 million (France). The dif-
ferences between the countries were primarily due to differences in dis-
count rates, causing the INMB to change between -65% to +62%,
incidence and mortality rates (epidemiology) of smoking-related diseases
(-43% to +35%) and utility weights. Impact also depended on the WTP
for a QALY and time horizon: at a low WTP or a short time horizon, the
resource use and unit costs of SCTs had the highest impact on INMB.
Conclusions: Although all INMBs were positive, there were signiﬁcant
differences across countries. These were primarily related to choice of
discount rate and epidemiology of diseases.
Keywords: bupropion, cost-effectiveness, cost-utility, incremental net
monetary beneﬁt, Markov model, nicotine replacement therapy, smoking
cessation, smoking-related diseases, transferability, varenicline, Western
Europe.
Introduction
An increasing number of regulatory agencies across the world
require evidence on the cost-effectiveness of new pharmacothera-
pies. All these agencies need results that represent their own
unique national or regional setting. Nevertheless, time and
budget constraints limit the number of clinical trials and eco-
nomic evaluations pharmaceutical companies can conduct in
potential markets. In addition, there is increased acknowledge-
ment of the limited external validity of country-speciﬁc cost-
effectiveness data. In recognition of these difﬁculties, ISPOR
initiated the Transferability of Economic Data Task Force. Their
mission was to develop good research practices on the transfer-
ability of economic data in health technology assessment [1].
The Task Force advocates the use of mathematical decision-
analytic models to assess setting-speciﬁc cost-effectiveness. These
models synthesize and structure evidence from diverse sources,
allow expanding the time horizon beyond that of a clinical trial,
as well as adapting and transferring results from one setting to
another [2,3]. For these reasons, models have been developed
to assess the long-term cost-effectiveness of smoking cessation
interventions.
A recent example is the BENESCO (Beneﬁts of Smoking
Cessation on Outcomes) model [4] which was developed by
Heron Evidence Development Ltd, to support the launch of
varenicline in various countries, e.g., The Netherlands [5],
Sweden [6], Belgium [Annemans et al., unpubl. ms.], Germany
[7], the UK [8], the Czech Republic [9], Korea [10], Japan [11],
and Denmark [12]. Interesting differences in the cost-
effectiveness of the various smoking cessation medications were
observed [13,14], which may relate to various sources of varia-
tion, for example the incidence and prevalence of smoking and
smoking-related diseases, characteristics of the population of
smokers, differences in absolute and relative unit costs of medi-
cations and health-care services and many other factors.
This study was designed to unravel the factors driving differ-
ences in cost-effectiveness of pharmacological smoking cessation
therapies (SCTs) between six European countries. The countries
included were The Netherlands, Belgium, Germany, Sweden, the
UK, and France, countries for which, at the start of the study,
country-speciﬁc input data of the model were available.
Methods
The Model
The projections of the effects of smoking cessation were based on
the BENESCO model [15], which is a probabilistic, updated, and
improved version of the Health and Economic Consequences of
Smoking model [16]. The BENESCO model simulates the con-
sequences of smoking and the beneﬁts of quitting in terms of
smoking-related morbidity, mortality, and associated medical
costs in a population. The model is structured as a Markov
model (cycle length 1 year) and follows a hypothetical cohort of
current smokers making a single attempt to quit smoking at the
beginning of the simulation. The cohort is followed from the time
of their quit attempt until all members of the cohort have died.
Individuals are classiﬁed into one of three smoking states, i.e.,
smoker, recent quitter (abstinent 1 to 5 years after successful quit
attempt), or long-term quitter. Transition probabilities between
smoking states in the ﬁrst year depend on cessation rates of the
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interventions, while the probabilities after 1 year depend on
relapse rates, which in turn depend on time since quitting. The
model simulates the age, gender, and smoking status-speciﬁc
incidence and mortality of four major diseases for which smoking
is a well-established risk factor: chronic obstructive pulmonary
disease (COPD), lung cancer, coronary heart disease (CHD), and
stroke. Smoking state-speciﬁc incidence and mortality rates were
calculated using relative risks [17,18]. The incidence and mortal-
ity rates for recent quitters were calculated using the relative risks
of former smokers versus nonsmokers, while the rates for long-
term quitters were assumed to be the same as those of never
smokers. Because COPD and lung cancer are chronic progressive
conditions, these diseases were given hierarchical prominence
over the other conditions with acute recurrent events. This means
that individuals with COPD or lung cancer remain in this state
until they die and cannot move to a CHD or stroke state, whereas
individuals with CHD or stroke can move to the COPD or lung
cancer state. As in all Markov models, states are mutually exclu-
sive, which means that a patient cannot have two diseases at the
same time. The model calculates the total number of smokers and
quitters that have one of the smoking-related diseases as well as
the number of deaths (due to one of the smoking-related diseases
and overall) over the time horizon of the simulation. Based on
these numbers, the total health-care costs associated with the
different disease states and the total number of (quality adjusted)
life years is calculated. The model uses three age bands: 18 to 34
years, 35 to 64 years, and 65 years and older. Subjects alive in the
model at age 99 years are all assumed to die in the next cycle. It is
assumed that there is no smoking-related morbidity or mortality
in the 18 to 34 years age class.
SCTs
We calculate the cost-effectiveness of three frequently used phar-
macological SCTs— nicotine replacement therapy (NRT), bupro-
pion, and varenicline—and unaided cessation. NRT is the generic
term for any form of smoking cessation aid which delivers a
measured dose of nicotine to the person using it. Examples
include the nicotine patch or nicotine gum. Bupropion is an
antidepressant used to support smoking cessation [19]. Vareni-
cline is designed to relieve symptoms of nicotine withdrawal
including cigarette craving and block the reinforcing effects of
continued nicotine use [20]. The 12-month continuous absti-
nence rates were based on a meta-analysis of available random-
ized controlled trials, where the SCTs were always given in
combination with counselling [5]. They were 5.0% for unaided
cessation, 14.8% for NRT, 17.0% for bupropion, and 22.4% for
varenicline. In all analyses, we assumed that 25% of smokers
undertake a single quit attempt, using one of the smoking cessa-
tion interventions, or unaided. It is this cohort that is followed
over lifetime.
Factors Affecting Transferability
A total of nine factors that could potentially cause differences in
cost-effectiveness between countries were investigated. Each
factor consists of a group of country-speciﬁc input parameters
which are varied simultaneously. Table 1 gives the most impor-
tant input parameters of each of the nine factors.
The nine country-speciﬁc factors include:
F1: Demography. This includes the total number of people older
than 18 years of age and the break-downs of the population
by gender and age-classes.
F2: Smoking Prevalence. This refers to the percentage of
smokers, nonsmokers, and former smokers in each age/
gender class.
F3: All-cause mortality. Mortality in the general population is
expressed as the all-cause mortality rate, which is the per-
centage of the total number of people in each age/gender
class that dies during a single year.
F4: Epidemiology of smoking-related diseases. The epidemiology
of smoking-related diseases consists of three elements: the
incidence rates, prevalence rates, and annual cause-speciﬁc
mortality rates by age/gender class. We applied the disease
deﬁnitions that were actually used in each country at the time
of writing the reimbursement dossiers for varenicline. To
identify COPD, all countries used ICD-10 codes J40–44, UK
and Sweden also used J47. To identify lung cancer, all coun-
tries used C33–34, except Sweden that deﬁned lung cancer as
C34. CHD is identiﬁed in all countries as I20–25. Stroke in
The Netherlands and Belgium is identiﬁed as I60–I69 plus
G45, in Sweden as I61 and I63, in Germany as I60, I61, I63
and I64, and in the UK and France as I60–I64.
Given the causal relationship, there is a strong association
between smoking prevalence and the epidemiology of smoking-
related diseases. To enter these two factors as independent factors
in the univariate analysis, we calculated the country-speciﬁc inci-
dence, prevalence, and mortality of smoking-related diseases
among nonsmokers, i.e., the country-speciﬁc baseline risk. This
was done using the country-speciﬁc epidemiology and smoking
prevalence, and the relative risks for smokers, former smokers,
and nonsmokers used within the model. When studying the
impact of the factor “epidemiology” in the univariate analysis,
the Dutch baseline-risk was replaced by the country-speciﬁc
baseline risk, which was then combined with the relative risks
and the Dutch smoking prevalence to estimate the incidence (or
prevalence or mortality) of smoking-related diseases among
smokers and ex-smokers.
F5: Costs of smoking-related diseases. The model makes a dis-
tinction between the ﬁrst-year costs and subsequent-year
costs for lung cancer, CHD, and stroke, diseases for which
high initial costs are generally followed by lower mainte-
nance costs. As COPD does not have (much) higher initial
costs, this distinction is not relevant for COPD.
F6: Resource use and F7: Unit costs of SCTs. The intervention
costs of SCTs are separated into two components: the amount
of resource use (i.e., medication and counselling) associated
with the SCTs and the unit costs of these resources. We have
investigated both these factors separately.
F8: Utility weights. The BENESCO model requires two catego-
ries of utility inputs: utility weights for the general, disease-
free (developed no smoking-related disease) population,
which vary by age, and the disease-speciﬁc utility weights,
which vary by type of smoking-related disease. The Nether-
lands is the only country in our sample for which country-
speciﬁc utility weights for both categories were provided.
Germany, Sweden, the UK, and France all have used the
provided default values within the model. Belgium has used
the general population utility weights from The Netherlands
and the default disease-speciﬁc utility values.
F9: Discount rates. All costs and outcomes are discounted using
the country-speciﬁc values that are recommended in the
national guidelines for economic evaluations. In the refer-
ence case, costs are discounted at 4%, outcomes at 1.5%.
We adopted a health-care perspective and included health-
care costs that are either covered from the health-care budgets or
paid for by patients. All prices and costs were inﬂated to 2006,
using the Harmonised Indices of Consumer Prices—all items
[100]. We also compensated for differences in purchasing power,
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Table 1 Main country-speciﬁc input parameters for each factor potentially contributing to between-country variation in cost-effectiveness of smoking
cessation interventions
The Netherlands Belgium Germany Sweden United Kingdom France
Population characteristics (age 18+, ¥ mln)
Population size 12.7 8.2 67.1 7.3 46.6 46.8
Number of smokers 3.54 2.25 18.61 1.51 12.70 11.53
As % of adult population 28% 27% 28% 21% 27% 25%
Cohort size: smokers making a quit attempt 0.88 0.56 4.65 0.38 3.17 2.88
F1: Demography
Males, 18 to 34 years 14.1% 13.9% 13.6% 15.4% 14.4% 14.6%
Males, 35 to 64 years 27.3% 25.5% 26.5% 24.7% 25.4% 24.6%
Males, 65+ years 7.6% 8.9% 7.9% 9.0% 8.7% 8.6%
Females, 18 to 34 years 13.8% 13.7% 13.5% 14.9% 14.3% 14.4%
Females, 35 to 64 years 26.8% 25.3% 25.8% 24.0% 26.1% 25.3%
Females, 65+ years 10.4% 12.7% 12.6% 12.0% 11.1% 12.4%
Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Source [21] [22] [23] [24] [25] [26]
F2: Smoking prevalence
Males, 18 to 34 years 32.3% 34.6% 38.7% 15.0% 32.6% 39.4%
Males, 35 to 64 years 34.1% 35.4% 36.0% 22.4% 27.7% 29.3%
Males, 65+ years 15.6% 19.2% 13.3% 15.4% 12.7% 10.2%
Females, 18 to 34 years 27.4% 26.1% 29.7% 23.0% 28.0% 31.2%
Females, 35 to 64 years 28.8% 27.8% 27.2% 26.8% 28.5% 21.8%
Females, 65+ years 12.3% 8.9% 6.4% 12.8% 26.7% 6.2%
Source [27] [28] [29] [24] [25] [30,31]
F3:All-cause mortality
Males, 18 to 34 years 0.06% 0.12% 0.08% 0.07% 0.09% 0.09%
Males, 35 to 64 years 0.40% 0.54% 0.58% 0.39% 0.47% 0.55%
Males, 65+ years 5.38% 5.48% 4.89% 4.14% 4.88% 4.72%
Females, 18 to 34 years 0.03% 0.04% 0.03% 0.03% 0.04% 0.04%
Females, 35 to 64 years 0.28% 0.29% 0.29% 0.25% 0.30% 0.25%
Females, 65+ years 4.57% 4.48% 4.67% 2.85% 3.87% 3.65%
Source [21] [22] [23] [24] [32] [26]
F4: Epidemiology: annual incidence rate of
COPD per 1,000 inhabitants
Males, 18 to 34 years 0.17 0.16 0.00 0.02 0.00 0.03
Males, 35 to 64 years 2.08 2.31 0.10 0.74 0.15 0.17
Males, 65+ years 9.68 12.77 3.26 15.22 3.82 1.73
Females, 18 to 34 years 0.17 0.17 0.00 0.02 0.00 0.01
Females, 35 to 64 years 2.13 2.63 0.06 0.97 0.11 0.09
Females, 65+ years 6.46 12.17 2.25 9.58 1.95 2.05
Source [33] [33] [29] [34] [35,36] [37–42]
F4: Epidemiology: annual incidence rate of
lung cancer per 1,000 inhabitants
Males, 18 to 34 years 0.01 0.01 0.01 0.01 0.00 0.01
Males, 35 to 64 years 0.56 0.61 0.69 0.69 0.56 1.00
Males, 65+ years 4.24 5.15 5.38 4.95 4.84 4.25
Females, 18 to 34 years 0.01 0.01 0.00 0.01 0.01 0.01
Females, 35 to 64 years 0.42 0.48 0.39 0.56 0.36 0.20
Females, 65+ years 1.07 1.71 1.43 1.88 1.63 0.82
Source [43] [43] [29,44–47] [34] [25] [48]
F4: Epidemiology: annual incidence rate of
CHD per 1,000 inhabitants, all events
Males, 18 to 34 years 0.35 0.33 0.80 0.05 0.04 0.00
Males, 35 to 64 years 7.60 7.95 8.36 6.97 2.32 4.27
Males, 65+ years 24.35 26.26 33.15 33.84 25.58 33.42
Females, 18 to 34 years 0.06 0.05 0.60 0.02 0.01 0.00
Females, 35 to 64 years 2.37 2.54 5.29 2.32 0.53 1.21
Females, 65+ years 15.29 17.44 25.76 20.84 15.48 15.45
Source [49] [49] [29,50] [34] [25,51] [52]
F4: Epidemiology: annual incidence rate of
CHD per 1,000 inhabitants, ﬁrst event only
Males, 18 to 34 years 0.33 0.32 0.46 0.04 0.04 0.00
Males, 35 to 64 years 5.69 5.95 4.86 4.39 1.60 3.80
Males, 65+ years 17.50 18.87 19.25 17.24 14.93 26.27
Females, 18 to 34 years 0.06 0.05 0.35 0.02 0.01 0.00
Females, 35 to 64 years 1.81 1.94 3.07 1.57 0.46 1.12
Females, 65+ years 11.42 13.04 14.96 12.11 11.27 13.42
Source [49] [49] [29,50] [34] [25,51,53] [52]
F4: Epidemiology: annual incidence rate of stroke
per 1,000 inhabitants, all stroke events
Males, 18 to 34 years 0.03 0.03 0.12 0.06 0.08 0.14
Males, 35 to 64 years 1.31 1.39 1.89 1.69 2.29 0.79
Males, 65+ years 11.69 12.61 17.80 14.67 13.25 9.07
Females, 18 to 34 years 0.10 0.10 0.03 0.05 0.07 0.13
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using the average exchange rates on January 2, July 3, and
December 31, 2006, and 2006 purchasing power parities [100].
Analyses
The starting point of all between-country comparisons were the
results of the BENESCO model populated with Dutch input data.
Hence, The Netherlands was the reference case. In a series of
univariate analyses we replaced the group of input parameters
belonging to the same factor by its country-speciﬁc estimates. We
changed one factor at a time; all other factors were kept constant
at the reference values. We compared the impact of each factor
on the outcomes. In the subsequent multivariate analysis, we
Table 1 Continued
The Netherlands Belgium Germany Sweden United Kingdom France
Females, 35 to 64 years 0.88 1.00 1.34 0.93 1.58 0.73
Females, 65+ years 11.43 12.71 11.95 13.23 12.28 6.19
Source [54] [54] [29] [34] [25] [55]
F4: Epidemiology: annual incidence rate of stroke
per 1,000 inhabitants, ﬁrst event only
Males, 18 to 34 years 0.03 0.03 0.06 0.05 0.06 0.00
Males, 35 to 64 years 1.19 1.25 0.99 1.44 1.73 0.43
Males, 65+ years 10.53 11.36 9.29 11.29 8.74 8.15
Females, 18 to 34 years 0.10 0.10 0.02 0.04 0.05 0.00
Females, 35 to 64 years 0.80 0.91 1.07 0.80 1.17 0.43
Females, 65+ years 10.52 11.70 9.51 10.66 8.03 5.07
Source [54] [54] [29] [34] [25] [55]
F5:Annual costs* per patient with a
smoking-related disease
COPD 1,036 1,928 2,245 2,907 1,127 2,220
Lung Cancer
First year 13,236 13,505 33,983 10,355 5,132 17,629
After ﬁrst year 13,236 13,505 33,983 5,502 5,132 17,629
CHD
First year 4,841 4,867 1,969 4,795 1,348 5,721
After ﬁrst year 2,949 796 985 1,374 1,348 5,721
Stroke
First year 23,119 7,685 10,741 7,056 22,006 9,641
After ﬁrst year 5,229 5,439 4,618 1,884 22,006 9,641
Source [56–59] [57,60–63] [29,64] †[65,66] [67–70] [71]
F6: Resource use: intervention costs using
different resource use across countries,
but equal unit costs*
Varenicline 391.79 304.79 294.59 391.79 381.59 294.59
Bupropion 327.81 244.81 226.60 335.51 160.30 230.61
NRT 323.35 213.94 207.00 298.79 234.56 231.05
Unaided cessation 0.00 0.00 0.00 0.00 0.00 0.00
Source [20,72] [73,74] [75] [19,76,77] [78]
F7: Unit costs: intervention costs using
different unit costs across countries,
but equal resource use*
Varenicline 391.79 391.78 337.28 401.90 290.62 390.60
Bupropion 327.81 277.42 292.22 350.92 285.02 327.15
NRT 323.35 311.05 317.13 365.76 213.15 387.03
Unaided cessation 0.00 0.00 0.00 0.00 0.00 0.00
Source [79,80] [73,74] [75] [19,76,77] [81]
F8: General population utility weights
m 18–34 0.910 0.910 0.930 0.930 0.930 0.930
m 35–64 0.910 0.910 0.877 0.877 0.877 0.877
m 65+ 0.820 0.820 0.800 0.800 0.800 0.800
f 18–34 0.920 0.920 0.910 0.910 0.910 0.910
f 35–64 0.890 0.890 0.853 0.853 0.853 0.853
f 65+ 0.760 0.760 0.770 0.770 0.770 0.770
Source [82–90]
F8: Disease-speciﬁc utility weights
COPD 0.690 0.760 0.760 0.760 0.760 0.760
Lung cancer ﬁrst year 0.610 0.610 0.610 0.610 0.610 0.610
Following years 0.500 0.500 0.500 0.500 0.500 0.500
CHD 0.710 0.760 0.760 0.760 0.760 0.760
Stroke ﬁrst year 0.540 0.740 0.740 0.740 0.740 0.740
Following years 0.290 0.150 0.150 0.150 0.150 0.150
Source [83–93]
F9: Discount rates
Costs 4.0% 3.0% 5.0% 3.0% 3.5% 3.0%
Outcomes 1.5% 1.5% 5.0% 3.0% 3.5% 0.0%
Source [94] [95] [96] [97] [98] [99]
*In 2006 Euros, accounting for differences in purchasing power; †Bolin K, Dozet A, unpubl. data.
COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; NRT, nicotine replacement therapy.
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consecutively enter parameters from the highest to the lowest
impact. Eventually, this results in models that are ﬁlled com-
pletely with country-speciﬁc parameters. In all analyses, the time
horizon is lifetime. Sensitivity analyses were done using different
time horizons and different threshold values of the willingness-
to-pay (WTP) for a quality adjusted life year (QALY).
Outcomes
Outcomes were presented as incremental costs, QALYs gained,
incremental cost-effectiveness ratios (ICERs), and incremental net
monetary beneﬁts (INMBs). The ICER is the difference in total
costs between two smoking cessation interventions, divided by the
difference in total QALYs. The percentage change in the INMB of
the reference case caused by each factor was our primary measure
of interest. The INMB was calculated as the difference in QALYs
between two interventions, times societies’ WTP, for a QALY
(threshold value) minus the difference in costs. The INMB was
calculated with a relatively low threshold value of €20,000 per
QALY. For each country, we have ranked all country-speciﬁc input
parameters according to the percentage of change in INMB com-
pared with the reference case. A rank order of 1 indicates that this
factor caused the INMB to change most; a rank order of 9
indicates that this factor had the least impact on the INMB.
We present the outcomes according to a hierarchy of effec-
tiveness of the interventions: NRT versus unaided cessation,
bupropion versus NRT, and varenicline versus bupropion. The
ranking was averaged over these three pair-wise comparisons.
Results
Reference Case
In Table 2, the outcomes of the reference case are given. The
ICER of NRT compared with unaided cessation was about
€1600 per QALY. Bupropion dominated NRT, and varenicline
dominated bupropion. Using a WTP of €20,000 per QALY, the
INMBs of all three comparisons were positive.
Univariate Analysis
F1: Demography. Demography inﬂuences the age and gender
distribution of the cohort of smokers that is followed over life-
time. If the cohort of smokers that attempts to quit becomes
older than in the reference case, the INMB and ICER worsen, for
all three pair-wise comparisons of smoking-cessation interven-
tions. This is primarily due to a decrease in QALYs that is greater
for the more effective intervention because the number of people
who remain disease free and survive to old age is greater for this
intervention. Table 3 summarizes these effects. Replacing the age
and gender distribution in the reference case by the country-
speciﬁc age and gender distribution caused the INMB of NRT
versus unaided cessation to change between -2.1% in Belgium
and -0.4% in Sweden. The change in INMB of bupropion versus
NRT varies from -1.7% in Belgium to -0.4% in Sweden. The
change in INMB of varenicline versus bupropion varies from
-1.8% in Belgium to -0.4% in Sweden (Fig. 1).
F2: Smoking prevalence. Like demography, smoking prevalence
primarily inﬂuences the age and gender distribution of the cohort
of smokers attempting to quit. When smoking prevalence among
the elderly gets higher, the cohort of smokers attempting to quit
becomes older and the INMB and the ICER worsen. Compared
with the reference case, the change in INMB for NRT versus
unaided cessation that is due to a change towards country-
speciﬁc smoking prevalence varies from -6.2% in Sweden to
+7.6% in France. The change in INMB for bupropion versus
NRT varies from -5.1% in Sweden to +6.3% in France. The
change in INMB for varenicline versus bupropion varies from
-5.4% in Sweden to +6.6% in France (Fig. 1).
F3: All-cause mortality. In countries where the all-cause mortal-
ity rate is lower (i.e., the life expectancy is higher) than in the
reference case, the INMBs of the smoking cessation interventions
Table 2 Lifetime outcomes of the Beneﬁts of Smoking Cessation on Outcomes model ﬁlled with Dutch* input data, expressed per 1000 smokers making
a quit attempt
NRT versus
unaided cessation
Bupropion
versus NRT
Varenicline
versus bupropion
Difference in total costs (€1000)† 126.7 -40.4 -44.7
Difference in QALYs 77.4 17.7 42.8
Incremental net monetary beneﬁt (INMB) (€1 mln)‡ 1.42 0.39 0.90
Incremental cost-effectiveness ratio (ICER) 1636.7 Dominant Dominant
*Outcomes differ from [5] because all cost inputs were updated to 2006 prices, Harmonised Indices of Consumer Prices was used; asthma exacerbations were excluded and the price of
varenicline was updated.
†Intervention costs plus total costs of smoking-related diseases.
‡WTP is €20,000.
NRT, nicotine replacement therapy; QALYs, quality adjusted life years;WTP, willingness-to-pay.
Table 3 Effect of changing the reference case input values to the
country-speciﬁc input values on cost-effectiveness outcomes compared
with the reference case
Effect on INMB and
ICER compared with
the reference case
F1: Demography
Older cohort Worsens
F2: Smoking prevalence
Higher smoking prevalence among elderly Worsens
F3:All-cause mortality
Lower mortality Improves
F4: Smoking-related disease epidemiology
Higher incidence Improves
Higher mortality Improves
F5: Costs of smoking-related diseases
Higher costs Improves
F6: Resources used for SCTs
Resource use of a more effective SCT increases
more than the resource use of a less effective SCT
Worsens
F7: Unit costs of SCTs
Unit cost of a more effective SCT increases more
than the unit costs a less effective SCT
Worsens
F8: Utility weights
Higher disease-speciﬁc utility weights Worsens
Lower general population utility weights Worsens
F9: Discount rates
Higher discount rates on costs Worsens
Higher discount rates on outcomes Worsens
INMB, incremental net monetary beneﬁt; ICER, incremental cost-effectiveness ratio; SCTs,
smoking cessation therapies.
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are higher and the ICERs improve, primarily because of higher
QALY gains. The increase in QALYs that result from a lower
mortality rate is largest for the most effective treatment, because
the number of people who stop smoking and remain disease free
is highest for this intervention. The change in INMB for NRT
versus unaided cessation because of a change in all-cause mor-
tality varies from -1.9% in Belgium to +12.9% in Sweden. The
change in INMB for bupropion versus NRT varies from -1.6%
in Belgium to +10.6% in Sweden. The change in INMB for
varenicline versus bupropion varies from -1.7% in Belgium to
+11.3% in Sweden (Fig. 1).
F4: Epidemiology of smoking-related diseases. In countries
where the incidence of all smoking-related diseases is higher than
in the reference case, the INMBs and ICERs improve, because
preventing more diseases results in higher QALY gains and
Belgium 
-2.1%
0.7%
-1.9%
15.2%
-0.7%
7.7%
0.9%
-13.7%
3.0%
-30% -20% -10% 0% 10% 20% 30%
F1
F2
F3
F4
F5
F6
F7
F8
F9
Germany 
-1.6%
5.0%
-0.5%
-11.1%
2.6%
8.2%
0.4%
-18.1%
-65.2%
-90% -60% -30% 0% 30% 60%
F1
F2
F3
F4
F5
F6
F7
F8
F9
Sweden 
-0.4%
-6.2%
12.9%
34.5%
0.8%
1.7%
-3.0%
-18.1%
-32.3%
-60% -40% -20% 0% 20% 40% 60%
F1
F2
F3
F4
F5
F6
F7
F8
F9
UK
-0.7%
-5.3%
3.8%
-11.3%
4.9%
6.2%
7.7%
-18.1%
-42.5%
-60% -40% -20% 0% 20% 40%
F1
F2
F3
F4
F5
F6
F7
F8
F9
France 
-1.1%
7.6%
4.8%
-43.2%
9.2%
6.5%
-4.5%
-18.1%
62.0%
-90.0% -60.0% -30.0% 0.0% 30.0% 60.0% 90.0%
F1
F2
F3
F4
F5
F6
F7
F8
F9
F1: Demography 
F2: Smoking prevalence 
F3: All-cause mortality 
F4: Epidemiology: incidence and mortality of 
smoking-related diseases 
F5: Costs of smoking related diseases 
F6: Resource use: intervention costs 
F7: Unit costs: intervention costs 
F8: Utilities 
F9: Discount rates
Figure 1 Relative change in incremental net monetary beneﬁts of nicotine replacement therapy versus unaided cessation of the reference case, caused by applying
each country-speciﬁc factor univariately.
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greater cost savings. The same holds for countries where the
mortality due to smoking-related diseases is higher. Change in
prevalence has only a limited effect on the INMB. The change
in INMB for NRT versus unaided cessation because of a change
in epidemiology varies from -43.2% in France to +34.5% in
Sweden. The change in INMB for bupropion versus NRT varies
from -35.6% in France to +28.5% in Sweden. The change in
INMB for varenicline versus bupropion varies from -37.7% in
France to +30.1% in Sweden (Fig. 1).
F5: Costs of smoking-related diseases. In countries where the
health-care costs of smoking-related diseases are higher than in
the reference case, the INMBs are higher and the ICERs improve,
because the savings from preventing these diseases increase. This
increase gets greater when the effectiveness of the smoking ces-
sation intervention improves. The change in INMB for NRT
versus unaided cessation because of a change in costs per patient
with a smoking-related disease varies from -0.7% in Belgium to
+9.2% in France. The change in INMB for bupropion versus
NRT varies from -0.6% in Belgium to +7.6% in France. The
change in INMB for varenicline versus bupropion varies from
-0.6% in Belgium to +8.0% in France (Fig. 1).
F6: Resource use and F7: Unit costs of SCTs. When the inter-
vention costs of a more effective SCT increase relatively more
than the intervention costs of a less effective treatment, the INMB
will go down and the cost-effectiveness will worsen. The change
in INMB for NRT versus unaided cessation because of a change
in the resource use component of the intervention costs varies
from +1.7% in Sweden to +8.2% in Germany. The change in
INMB for bupropion versus NRT varies from -8.2% in Sweden
to +20.0% in the UK. The change in INMB for varenicline versus
bupropion varies from -17.5% in the UK to +0.9% in Sweden.
The change in INMB for NRT versus unaided cessation
because of a change in the unit cost component of the interven-
tion costs varies from -4.5% in France to +7.7% in the UK. The
change in INMB for bupropion versus NRT varies from -17.1%
in the UK to +16.3% in France. The change in INMB for vareni-
cline versus bupropion varies from -5.6% in Belgium to +6.5%
in the UK (Fig. 1).
F8: Utilities. In countries where the utility weights of the
smoking-related diseases are higher than in the reference case, the
QALY gains from preventing these diseases are lower. The reduc-
tion in QALY gain is greatest for the intervention with the highest
effectiveness. Thus, higher disease-speciﬁc utility weights lead to
lower INMBs and a worsening of the cost-effectiveness. This
applies to all ﬁve countries in our analysis, because the reference
case represents the only country that has changed the model’s
default utility values.
If the utility weights for the general, disease-free population
of a country are lower than in the reference case, the QALY gains
from preventing a smoking-related disease are lower. Again, the
reduction in QALY gains is greater if the treatment is more
effective because more people stay disease free and their live years
are thus weighted with the lower utility weights. This causes the
INMBs to go down and the ICERs to worsen. The change in
INMB for NRT versus unaided cessation because of a change in
utility weights varies from -18.1% in Germany, Sweden, the UK,
and France, to -13.7% in Belgium. The change in INMB for
bupropion versus NRT varies from -14.9% in Germany,
Sweden, the UK and France, to -11.3% in Belgium. The change
in INMB for varenicline versus bupropion varies from -15.8% in
Germany, Sweden, the UK, and France, to -12.0% in Belgium
(Fig. 1).
F9: Discount rates. In countries where the costs and outcomes
are discounted more than in the reference case, the INMBs and
the ICERs worsen because the cost savings and QALY gains of
smoking cessation that occur far into the future are reduced. The
change in INMB for NRT versus unaided cessation because of a
change towards country-speciﬁc discount rates varies from
-65.2% in Germany to +62.0% in Sweden. The change in INMB
for bupropion versus NRT varies from -53.7% in Germany to
+51.1% in Sweden. The change in INMB for varenicline versus
bupropion varies from -56.9% in Germany to +54.1% in
Sweden (Fig. 1).
Ranking of Impact on INMB
The ranking of factors according to their impact on the INMB of
NRT versus unaided cessation is largely similar for the compari-
sons bupropion versus NRT and varenicline versus bupropion.
Table 4 shows the rank order when averaged over all three pair-
wise treatment comparisons. The ﬁrst row shows the rank orders
after averaging the impact of each factor over all countries. When
substituting the reference case input univariately by country-
speciﬁc input, F9: discount rates had the biggest impact on the
cost-effectiveness. This is followed by F4: epidemiology and F8:
utility weights. The least important factor in terms of its effect on
the INMB is F1: demography, i.e., the age/gender distribution of
the cohort of smokers making a quit attempt.
Sensitivity Analysis: Impact of Using a Different
Time Horizon
A shorter time horizon changes the importance of the various
causes of variability in cost-effectiveness between countries. The
importance of the three factors with the largest long-term impact,
i.e., F9: discount rates, F8: utility weights, and F3: all-cause
mortality decreases. Using a time span of 2 or 10 years, the two
most important factors become the two factors determining the
costs of smoking cessation treatment: F6: resources used and F7:
unit costs. These factors become so important because a time
horizon of 2 and 10 years is insufﬁcient to capture the full gains
in QALYs and savings in costs that result from the prevention of
smoking-related diseases. In other words, time has been insufﬁ-
cient to fully get the returns on the investments in SCT.
Sensitivity Analysis: Impact of Using a Different
Threshold Value
Using different threshold values to calculate the NMB also
changes the rank order of the factors. When the threshold value
increases, the factors with a large inﬂuence on the QALYs, i.e.,
all-cause mortality, smoking prevalence, and demography,
become more important. When the threshold value decreases,
factors with a large inﬂuence on costs become more important.
This includes resources used for the smoking cessation treat-
ments, unit costs, and costs of smoking-related diseases. The
discount rates remain important, irrespective of the threshold
value. For threshold values of €5000 or higher, discounting is the
single most important factor. Using a threshold value of €1000 or
lower, the discount rate becomes the fourth most important
factor. For a threshold value of €1000 or lower, the most impor-
tant factor is the resources used to deliver SCT, followed by costs
of smoking-related disease.
Multivariate Analysis
In the multivariate analysis, we enter all country-speciﬁc input
parameters at the same time. Table 5 shows how the INMB
differs between countries when fully accounting for all known
between-country differences.
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In Belgium, the decrease in INMB due to higher disease-
speciﬁc utilities is offset by an increase in the INMB because of a
higher incidence of all smoking-related diseases. As a result, the
INMBs increase, except for varenicline versus buproprion
because the difference in unit costs between the two SCTs is
greater than in The Netherlands.
In Germany, the INMBs of all three pair-wise comparisons
decrease primarily because of the relatively high discount rate for
costs and outcomes. Other causes are a lower incidence of
COPD, higher disease-speciﬁc utility values and lower general
population utility values.
In Sweden, the INMB is also lower than in the reference case
for all pair-wise comparisons, because of higher utility weights
for the smoking-related diseases and because QALYs were dis-
counted at 3.5% instead of 1.5%. This decrease offsets the
increase in INMB caused by lower all-cause mortality rates and
higher incidence rates for all smoking-related diseases in most
age/gender classes.
In the UK, the INMB of all three pair-wise comparisons is
lower than in the reference case, primarily because of a higher
discount rate (3%) for outcomes, higher utility weights for the
smoking-related diseases and a lower incidence of COPD.
In France, lower smoking-related disease mortality, higher
disease-speciﬁc utility values, and lower general population
utility values cause the INMB of all three pair-wise comparisons
to decrease. Nevertheless, the effect of no discounting (0%) on
outcomes has such a large effect that the INMB is higher than in
the reference case.
Figure 2 shows the differences between countries in terms of
ICERs for NRT versus unaided cessation. Incremental costs per
QALYs gained in the reference case were estimated to be €1600,
represented by the dotted line. This ICER improved for Belgium
(BE), Sweden (SE), and the UK; it worsened for Germany (DE)
and France (FR). Note that the ICER in Sweden and the UK
improved whereas the INMB decreased. In France, the ICER
worsened whereas the INMB improved. This is due to the valu-
ation of the QALY gains with €20,000 per QALY, as a result of
which a decrease in QALYs, as in the UK, has a much greater
impact on the INMB than on the ICER.
Discussion
Many factors should be taken into account when transferring
cost-effectiveness results across countries and settings and there
are many interactions between these factors. This stresses the
importance of carefully considering whether foreign results can
be applied and adapted to its own setting. In this paper, we
systematically investigated the impact of nine groups of country-
speciﬁc model input parameters (factors) on the cross-country
variability in long-term cost-effectiveness of pharmacological
smoking cessation interventions. An earlier article [13] has
already shown that outcomes from cost-effectiveness studies on
SCTs differ considerably between countries, but causes were not
Table 4 Univariate ranking of factors according to the percentage change in incremental net monetary beneﬁt, averaged over the three pair-wise
comparisons of smoking cessation therapies, using a threshold value €20,000 per quality adjusted life year and a lifetime horizon, unless otherwise stated
F9 F4 F8 F6 F7 F2 F3 F5 F1
Discount
rates Epidemiology
Utility
weights
Resource
use
Unit
costs
Smoking
prevalence
All-cause
mortality
Costs of
smoking-related
diseases Demography
Rank order averaged
over all countries
1 2 3 4 5 6 7 8 9
Rank order for each country
Belgium 5 1 2 4 3 8 7 9 6
Germany 1 3 2 5 6 4 9 7 8
Sweden 2 1 3 6 7 5 4 8 9
United Kingdom 1 5 2 3 4 6 8 7 9
France 1 2 3 8 5 6 7 4 9
Rank order averaged over
all countries at different
time horizons
2 years 7 4 5 2 1 6 9 3 8
10 years 5 3 4 1 2 7 9 6 8
Lifetime 1 2 3 4 5 6 7 8 9
Rank order averaged over
all countries at different
threshold values
€100 4 5 9 1 2 6 7 3 8
€500 4 5 7 1 2 6 8 3 9
€1,000 4 5 6 1 2 7 8 3 9
€5,000 1 2 5 3 4 7 8 6 9
€10,000 1 2 3 4 5 7 8 6 9
€20,000 1 2 3 4 5 6 7 8 9
€50,000 1 2 3 6 7 4 5 8 9
€100,000 1 2 3 7 6 5 4 9 8
Table 5 Incremental Net Monetary Beneﬁt (INMB) per 1000 smokers
undertaking a quit attempt, using a threshold of €20,000 per quality
adjusted life year, for three pair-wise smoking cessation therapy compari-
sons, inﬂuenced by all nine identiﬁed factors
INMB (x€1 mln)
NRT versus
unaided
cessation
Bupropion
versus NRT
Varenicline
versus
bupropion
The Netherlands 1.42 0.39 0.90
Belgium 1.46 0.45 0.86
Germany 0.39 0.17 0.32
Sweden 1.29 0.22 0.82
UK 0.95 0.25 0.54
France 1.47 0.64 1.01
NRT, nicotine replacement therapy.
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unravelled. Among the factors that we have investigated, the
choice of discount rate was the factor contributing the most to
the between-country differences in cost-effectiveness, followed by
the incidence and mortality of smoking-related diseases and the
utility values used to calculate QALYs.
It is important to note that the importance of a factor in terms
of its impact on the INMB depends on the WTP for a QALY. At
a WTP of €20,000 per QALY, the impact of between-country
differences in the cost parameters is relatively low, because the
changes in the INMB are largely driven by factors affecting the
QALYs. At lower values of the WTP for a QALY, the costs of
SCTs, in terms of both the unit costs and resource use, as well as
the costs of smoking-related diseases, become much more impor-
tant. Irrespective of the WTP for a QALY, the impact of differ-
ences between countries in demography and all-cause mortality
in the INMBs is small, because the differences between the coun-
tries investigated were relatively small and do not greatly alter
the cohort of smokers undertaking a quit attempt.
Despite the differences between countries, all pair-wise treat-
ment comparisons in our study showed that the more effective
smoking cessation treatments were also cost-effective, and in
some case even cost-saving. INMBs were positive and ICERs
were consistently below €5300 per QALY gained. Hence, there
are strong health economic arguments to support these treat-
ments across all countries.
It is further relevant to note the differences between the
changes in the ICERs and the changes in the INMBs compared
with the reference case, which stresses the importance of the
threshold value for a QALY in decision-making. Using the
change in INMB instead of the change in ICER as a measure of
the importance of a country-speciﬁc factor gives relatively greater
weight to changes in QALYs. We have seen that the larger
emphasis on QALYs in the INMB also affects the relative impor-
tance of a factor. For example, applying the Swedish discount
rates (3% for costs and outcomes) causes both the incremental
costs and QALYs gained to decrease. This leads to a change
in ICER of -3% and thus a slight improvement of cost-
effectiveness, whereas the INMB is a signiﬁcant 32% lower.
In each country, we have used the same base-case estimates of
the 12-month continuous abstinence rates [5]. This is based on
the assumption that the pure biological effect of a drug can be
expected to be the same, irrespective of the country. Otherwise
we have used as many country-speciﬁc estimates of model input
parameters as available. Some of the input data were very difﬁ-
cult to compare across countries. For example, smoking preva-
lence data may differ, because countries use different deﬁnitions
and methods to determine the number of current smokers, like
including only daily smokers or also including irregular smokers.
In The Netherlands for example, a smoker is deﬁned as some-
body that has smoked in the 7 days before being asked [101],
while in Belgium, people are asked whether they have smoked
100 cigarettes during their lives and whether they consider them-
selves a smoker or not [102]. In addition, the epidemiological
data on smoking-related diseases are difﬁcult to compare across
countries. Different countries also used different deﬁnitions of
the four diseases included in the model, especially with respect to
COPD and CHD. For example, COPD was identiﬁed with
ICD-10 code J40–44 in The Netherlands, but as J40–44 plus J47
in Sweden. Such a difference in deﬁnition could potentially be a
source of the difference in reported epidemiology and its associ-
ated costs between countries. Furthermore, not all countries dis-
tinguish between the ﬁrst-year costs of lung cancer, CHD and
stroke and the costs of these diseases in later years, often because
these data are not available. Such differences complicate the
comparison of cost-effectiveness between countries. Neverthe-
less, we have deliberately chosen to use the deﬁnitions of the
smoking-related diseases and the associated cost that were actu-
ally applied at the time of writing the country-speciﬁc reimburse-
Figure 2 Cost effectiveness per 1000 smokers with a quit attempt of nicotine replacement therapy versus unaided cessation inﬂuenced by all nine identiﬁed factors.
Dotted line shows all points with the same incremental cost-effectiveness ratios (ICER) as NL (€1,637 / QALY). ICERs: BE = €207 / QALY; GE = €5184 / QALY;
SE = €495 / QALY; UK = -/-€6,566 / QALY; FR = €2125 / QALY.
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ment dossiers for varenicline. By doing so, we highlight best the
differences between countries and the inﬂuence of these differ-
ences on cost-effectiveness and cost-beneﬁt estimates as they
drive actual decision-making.
Despite its large inﬂuence on the outcomes, in only one of our
six countries, The Netherlands, country-speciﬁc utility weights
were available. This lack of country-speciﬁc utility data is prob-
ably due to the difﬁculty to collect these data and the assumption
that utility values for a speciﬁc health state will probably not
differ much between countries. Nevertheless, as this study shows,
it is worthwhile to invest more time and resources in ﬁnding
country-speciﬁc utility weights, because their impact on the
INMB is large, especially at higher levels of the threshold value of
a QALY.
The Transferability of Economic Data Task Force from
ISPOR states on their webpage [103] that one of the most impor-
tant questions to be answered with regard to transferability is
“[w]hich elements of economic data vary most from setting to
setting?” The results from this study suggest that it is not only
important to see which factors vary, but also how much this
variation in factors causes variation in cost-effectiveness. The
factors that cause the most variation in cost-effectiveness do not
necessarily have to be the same as the factors that vary most
themselves. For example, the unit costs of the smoking cessation
drugs differ considerably between countries, but the impact on
the cost-effectiveness is limited when adopting a lifetime time
horizon. We spent considerable time and effort on identifying
data sources, adjusting input data to ﬁt into the model and
especially assessing the comparability of input parameters
between countries. Based on this observation, we wholeheartedly
agree with the concluding remark of the Task Force that “those
developing national guidelines for economic evaluations should
think carefully about the need for local data or methods, since
this increases the burden on those undertaking studies in multiple
jurisdictions.” The results of our study underline that, when
studying the cost-effectiveness of smoking cessation, there is a
need for local data even for countries within a similar region of
the world.
Source of ﬁnancial support: The study was sponsored by an unrestricted
grant from Pﬁzer.
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